Abstract
This report summarized the discussion on:
- Routine PCV13 use among adults >65 years old: summary of evidence, cost‐effectiveness, and GRADE conclusions
- Considerations for PCV13 use among adults and policy options
- Recommendations for PCV13 use among adults
Agenda & Minutes
Americas
United States of America
Pneumococcal disease
